349 related articles for article (PubMed ID: 34419602)
21. Topography of Simulated Intestinal Equilibrium Solubility.
Dunn C; Perrier J; Khadra I; Wilson CG; Halbert GW
Mol Pharm; 2019 May; 16(5):1890-1905. PubMed ID: 30848917
[TBL] [Abstract][Full Text] [Related]
22. Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid.
Fagerberg JH; Karlsson E; Ulander J; Hanisch G; Bergström CA
Pharm Res; 2015 Feb; 32(2):578-89. PubMed ID: 25186438
[TBL] [Abstract][Full Text] [Related]
23. Human intestinal fluid factors affecting intestinal drug permeation in vitro.
Riethorst D; Brouwers J; Motmans J; Augustijns P
Eur J Pharm Sci; 2018 Aug; 121():338-346. PubMed ID: 29902511
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability.
Wuyts B; Riethorst D; Brouwers J; Tack J; Annaert P; Augustijns P
Int J Pharm; 2015 Jan; 478(2):736-44. PubMed ID: 25510602
[TBL] [Abstract][Full Text] [Related]
25. Mimicking regional and fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: The impact of pH and simulated intestinal fluids on drug permeability.
Falavigna M; Klitgaard M; Steene E; Flaten GE
Eur J Pharm Sci; 2019 Apr; 132():44-54. PubMed ID: 30822502
[TBL] [Abstract][Full Text] [Related]
26. Influence of Physiological Gastrointestinal Surfactant Ratio on the Equilibrium Solubility of BCS Class II Drugs Investigated Using a Four Component Mixture Design.
Zhou Z; Dunn C; Khadra I; Wilson CG; Halbert GW
Mol Pharm; 2017 Dec; 14(12):4132-4144. PubMed ID: 28749696
[TBL] [Abstract][Full Text] [Related]
27. Exploring drug solubility in fasted human intestinal fluid aspirates: Impact of inter-individual variability, sampling site and dilution.
de la Cruz-Moreno MP; Montejo C; Aguilar-Ros A; Dewe W; Beck B; Stappaerts J; Tack J; Augustijns P
Int J Pharm; 2017 Aug; 528(1-2):471-484. PubMed ID: 28591618
[TBL] [Abstract][Full Text] [Related]
28. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
Fuchs A; Leigh M; Kloefer B; Dressman JB
Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
[TBL] [Abstract][Full Text] [Related]
29. Crystallization from Supersaturated Solutions: Role of Lecithin and Composite Simulated Intestinal Fluid.
Indulkar AS; Gao Y; Raina SA; Zhang GGZ; Taylor LS
Pharm Res; 2018 Jun; 35(8):158. PubMed ID: 29916053
[TBL] [Abstract][Full Text] [Related]
30. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
[TBL] [Abstract][Full Text] [Related]
31. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
Madsen CM; Boyd B; Rades T; Müllertz A
Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
[TBL] [Abstract][Full Text] [Related]
32. Intestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions.
Fagerberg JH; Bergström CA
Ther Deliv; 2015; 6(8):935-59. PubMed ID: 26316058
[TBL] [Abstract][Full Text] [Related]
33. An In-Depth View into Human Intestinal Fluid Colloids: Intersubject Variability in Relation to Composition.
Riethorst D; Baatsen P; Remijn C; Mitra A; Tack J; Brouwers J; Augustijns P
Mol Pharm; 2016 Oct; 13(10):3484-3493. PubMed ID: 27576295
[TBL] [Abstract][Full Text] [Related]
34. Drug solubilization in dog intestinal fluids with and without administration of lipid-based formulations.
Parrow A; Kabedev A; Larsson P; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2024 Jul; 371():555-569. PubMed ID: 38844179
[TBL] [Abstract][Full Text] [Related]
35. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
[TBL] [Abstract][Full Text] [Related]
36. Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development.
Khoshakhlagh P; Johnson R; Langguth P; Nawroth T; Schmueser L; Hellmann N; Decker H; Szekely NK
J Pharm Sci; 2015 Jul; 104(7):2213-24. PubMed ID: 25964103
[TBL] [Abstract][Full Text] [Related]
37. Characterization of neonatal and infant enterostomy fluids - part II: Drug solubility.
de Waal T; Brouwers J; Rayyan M; Stillhart C; Vinarova L; Vinarov Z; Augustijns P
Int J Pharm; 2023 Jul; 642():123141. PubMed ID: 37321462
[TBL] [Abstract][Full Text] [Related]
38. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
Lennernäs H
Curr Drug Metab; 2007 Oct; 8(7):645-57. PubMed ID: 17979653
[TBL] [Abstract][Full Text] [Related]
39. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
Jones HM; Parrott N; Ohlenbusch G; Lavé T
Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
[TBL] [Abstract][Full Text] [Related]
40. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids.
Persson EM; Gustafsson AS; Carlsson AS; Nilsson RG; Knutson L; Forsell P; Hanisch G; Lennernäs H; Abrahamsson B
Pharm Res; 2005 Dec; 22(12):2141-51. PubMed ID: 16247711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
